Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07433400

Long-term Progression of Patients Treated and Monitored for Relapsed or Refractory Ph+ ALL

The objective of this retrospective study is to examine the outcome of patients who relapse with Ph+ ALL and to potentially identify response profiles in order toadvance the treatment regimens that can be offered.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Ph Positive ALL

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age >= 18
  • Relapse or refractory Ph1 ALL

Exclusion criteria

  • none

Treatment and study plan

Primary outcomes

  1. Long term survival

    Time frame: 5 years

Secondary outcomes

  1. 10 year-survival

    Time frame: 10 years

  2. Molecular response (BCR::ABL1 ratio)

    Time frame: At the end of each line of treatment, at each relapse, at 5 years after the last relapse, at 10 years after the last relapse

    Molecular response is assessed using BCR::ABL1 ratio, on bone marrow if available (if not, on blood)

  3. Hematologic response

    Time frame: At the end of each line of treatment, at each relapse, at 5 years after the last relapse, at 10 years after the last relapse

    Hematologic response is defined by less than 5% of blasts on bone marrow aspiration

  4. Death date

    Time frame: Up to 10 years

  5. Cause of death

    Time frame: Up to 10 years

    Cause of death can be : 1)disease, 2)complications related to treatment except bone marrow transplant, 3)Hematopoietic Stem Cells Transplantation related, 4)other

  6. Treatment characteristics (treatment name)

    Time frame: At day 1 of each new treatment of relapse

    Name of chemotherapy or immunotherapy used

  7. Treatment characteristics (treatment dates)

    Time frame: At day 1 and at the end of each line of treatment of relapse

    Start date and end date of treatment

  8. Treatment characteristics (dose)

    Time frame: At day 1 of each new treatment of relapse

    Dose of each treatment

Study contacts

Contact information is provided by the study sponsor or research team.

Aline SCHMIDT, MD/PhD

CONTACT

[email protected]

241354482 ext. 33

Véronique LHERITIER, Central coordination

CONTACT

[email protected]

0478862239 ext. 33

Sponsors and collaborators

Lead sponsor

Group for Research in Adult Acute Lymphoblastic Leukemia

Other

Registry information

Official study title

Retrospective Study of the Long-term Progression of Patients Treated and Monitored for Relapsed or Refractory Ph+ ALL

Acronym: EVOLALPh1

Important dates

Study start
2025
Primary completion
2035
Study completion
2035
First posted
Feb 25, 2026
Registry last updated
Feb 25, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.